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Burden of disease of human Papillomavirus (HPV): 
hospitalizations in Marche and Veneto regions. An observational 
study 
 
Abstract: 
 
Background and Objectives: HPV (Human Papillomavirus) is the most often responsible virus for 
sexually transmitted infections. The burden of HPV-related diseases on hospital resources 
represents a major public health problem. The aim of this study was to assess the economic burden 
of HPV-related diseases (Anal cancer, Genital cancer, Genital warts, Oropharyngeal cancer) on 
hospitals resources in two Italian regions. Methods: a retrospective, non-randomized, observational 
study was developed in Marche and Veneto Regions, based on patients receiving hospitalization 
between 2008 and 2011. All hospitalizations were identified through administrative archives, 
according to the International Classification of Diseases (ICD-9 CM) to which a defined tariff was 
assigned. Results: we identified 5,299 hospitalized patients in Veneto and 1,735 in Marche Region. 
The mean annual hospitalization rate was 49.44 per 100,000 individuals in Veneto and 48.41 in 
Marche. The total mean annual cost attributable to HPV-related diseases was € 5,78 (SD 0,80) 
million in Veneto and €2,24 (SD 0.17) million in Marche. Costs associated with genital cancer 
amounted to €1,61 million in Veneto and €1,06 million in Marche (28% and 47% of total mean 
annual cost respectively). Oropharyngeal cancer accounted for 36% in Veneto (€ 2,08 million) and 
28% in Marche (€ 632,645). Hospitalization costs related to Anal cancer were €882,567 in Veneto 
and €377,719 in Marche; Genital warts accounted for €1,19 million in Veneto and €171,406 in 
Marche. Finally, the mean cost per patient was €4,364 in Veneto and €5,176 in Marche. Conclusions: 
The present work estimated the cost of HPV-related diseases for hospitalized patients in two Italian 
regions. The considerable estimated annual economic burden is a powerful driver for the 
governance of the public health sector. 
 
Key Points: 
1) The economic burden and hospitalization rates associated with HPV-related diseases were 
estimated from a regional perspective in Italy. 
2) Between 2008 and 2011 resources allocated and hospitalization rates highlighted a decreasing 
trend in both Veneto and Marche regions. 
3) Over 72% of hospital admissions were strictly linked to HPV and caused a mean annual burden of 
€3,89 million in Veneto and €1,60 million in Marche. 
1. Background and Objectives:  
HPV (Human Papillomavirus) is the most often responsible virus for sexually transmitted infection. 
As of today, more than 100 types of papillomavirus infecting human beings have been identified. Of 
these, about 40% are associated with a wide range of genital diseases [1]. It was estimated that 
about 75% of sexually-active women are infected with any type of HPV virus during their lifetime 
[2]. Most infections are transient and asymptomatic however, in some cases, HPV involves a high-
oncogenic risk associated with the onset of cancers. When this happens the infection can progress 
to pre-cancerous and cancerous lesions. In particular, genotypes 16 and 18 are highly-risky virus 
variances, causing 70% of invasive cervical cancer and dysplasia globally [3, 4]. Overall, HPV virus is 
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responsible for 88% of anal cancers in both sexes, 70% of vaginal cancers, 43% of vulvar cancers and 
50% of penis cancers [5]. 
 
Many studies have been conducted in Italy on the prevalence and incidence of HPV infections [6-8]. 
However, these works often reported heterogeneous data due to the different populations 
analysed. Therefore, as of today there are no epidemiological studies taking into account a 
representative sample of the whole Italian population. A systematic revision of the literature tried 
to systematize the available epidemiological and economic information in the specific national 
context, estimating an annual direct cost associated with the main HPV-related diseases higher than 
€ 528,6 million (€ 480,1 - € 686,2 million range) [4]. A study conducted in Veneto examining the 
hospitalization rates of the different HPV-related diseases in a cohort of 5 million citizens showed 
that the burden of HPV-related diseases on hospital resources is a major public health problem [3]. 
 
The objective of this study was to estimate the overall and average economic impact per patient in 
two Italian regions, Veneto and Marche, between 2008 and 2011. For this purpose, hospitalizations 
associated with HPV-related diseases were analysed based on the administrative data of the two 
examined regions. 
2. Methods: 
 
This is an observational retrospective study based on data extracted from the health information 
system of Veneto and Marche regions. Hospital discharge record (HDR) referred to the period 2008-
2011 were analysed in order to identify hospitalization rates and the costs associated with HPV-
related diseases. Information related to the hospital discharges of all accredited public and private 
hospitals in Veneto and Marche, both in ordinary and day-care regime, were taken into account.  
 
Total costs related to hospitalizations were calculated using the diagnosis-related groups (DRGs) of 
hospitalized patients at the time of their discharge based on their age, gender and the consumption 
of resources during their hospital stay. According to the DRG-based reimbursement system, every 
hospitalized patient was attributed to a group of diagnostically homogeneous cases so that patients 
with the same DRG were assigned the same reimbursement charges. Specifically, we included 
hospitalizations related to resident patients in Veneto or Marche region, aged ≥18 and presenting 
one of the following International Classification of Diseases, 9th revision – Clinical Modification (ICD-
9-CM) codes as primary or secondary diagnosis: Genital warts: “Condyloma acuminatum” (078.11); 
“Anal cancers” (154.2-154.8); Oropharyngeal cancers: “Oropharyngeal cancer” (146.0-146.9) and 
“Head, face and neck cancers” (171.0); Genital cancers: “Penis cancer” (187.1-187.9) and “Cervical 
cancer” (180.0-180.9). 
HPV-related hospitalization rates referred to the overall population were calculated comparing the 
number of hospitalized patients, broken down by type and age, to the corresponding resident 
population at the beginning of the discharge year [9].  
In addition, a further estimation of the hospitalization rates and costs strictly linked to the presence 
of the HPV virus, was calculated by applying diagnosis-specific weights obtained from literature 
(Table 1). Specifically, it was assumed that 100% of the hospitalizations due to “Condiloma 
acuminatum” (Genital warts) [10, 11] and “Cervical cancers” were strictly associated with HPV [1, 
12] compared to 50% of hospitalizations due to “Penis cancer” [5], 77% to “Anal cancer” [5], and 
26% to “Oropharyngeal cancer” [13]. The diagnosis-specific weights were applied to the 
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hospitalizations per single diagnosis and this allowed our analysis to obtain a more specific 
estimation of the economic burden strictly related to HPV virus. 
The data analysis was generated using SAS software, Version 9.2 of the SAS System for Windows, 
Copyright © 2002-2008 SAS Institute Inc. (SAS Institute, 2008). Personal data were replaced with a 
random series of codes, in order to anonymize the database in compliance with the Italian privacy 
law.  
 
 
Table 1: weights used for HPV-strictly related diseases calculation 
 
Diagnosis Male Ref. Female Ref. 
Anal cancer 77% (66%-88%) [14] 77% (66%-88%) [14] 
Genital cancer 52% (37,6%-66%) [14] 100% [1,12] 
Genital warts 100% [10,11] 100% [10,11] 
Oropharyngeal cancer 26% (24%-27%) [13] 26% (24%-27%) [13] 
 
 
3. Results: 
 
A total of 10,586 hospitalizations was recorded between 2008 and 2011 in Veneto and Marche 
region, 8,044 (76%) and 2,542 (24%) respectively. Overall, 45.7% were referred to male patients, 
while 54.3% to females. In Table 2, hospitalizations are reported by age, sex and diagnosis for each 
region separately. 
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Table 2: HPV-related hospitalizations in Veneto and Marche (2008-2011)    
 
Total 
N=8,044 
Anal  
cancer 
N=1,016 
Genital 
cancer 
N=1,742 
Genital  
warts 
N=2,647 
Oropharyngeal 
cancer 
N=2,639 
VENETO  n % N % n % n % n % 
Sex           
Males 3,857 47.9 488 48.0 376 21.6 971 36.7 2,022 76.6 
Females 4,187 52.1 528 52.0 1,366 78.4 1,676 63.3 617 23.4 
Age group           
18-24 571 7.1 1 0.1 12 0.7 547 20.7 11 0.4 
25-44 2,115 26.3 66 6.5 406 23.3 1,570 59.3 73 2.8 
45-64 2,882 35.8 340 33.5 713 40.9 452 17.1 1,377 52.2 
65-74 1,414 17.6 274 27.0 297 17.0 54 2.0 789 29.9 
75-84 817 10.2 228 22.4 254 14.6 22 0.8 313 11.9 
85+ 245 3.0 107 10.5 60 3.4 2 0.1 76 2.9 
 
Total 
N=2,542 
Anal  
cancer 
N=362 
Genital 
cancer 
N=1,230 
Genital  
warts 
N=442 
Oropharyngeal 
cancer 
N=508 
MARCHE  n % N % n % n % n % 
Sex           
Males 981 38.6 187 51.7 209 17.0 203 45.9 382 75.2 
Females 1561 61.4 175 48.3 1021 83.0 239 54.1 126 24.8 
Age group           
18-24 123 4.8 0 0 7 0.6 100 22.6 16 3.1 
25-44 673 26.5 32 8.8 352 28.6 261 59.0 28 5.5 
45-64 890 35.0 134 37.0 482 39.2 68 15.4 206 40.6 
65-74 439 17.3 101 27.9 191 15.5 10 2.3 137 27.0 
75-84 310 12.2 69 19.1 155 12.6 2 0.5 84 16.5 
85+ 107 4.2 26 7.2 43 3.5 1 0.2 37 7.3 
      
 
 
Between 1st January 2008 and 31st December 2011 7,034 patients were hospitalized with potential 
HPV-related diseases: 5,299 in Veneto (75.3%) and 1,735 in Marche (24.7%). Every year about 1,325 
patients were hospitalized in Veneto and 434 in Marche. The most frequent diseases were genital 
warts in Veneto (2,275 patients) and genital cancer in Marche (728 patients). 
On average, from 2008 to 2011, 1.68 hospitalizations per patient were estimated in Marche and 
1.47 in Veneto. The majority of hospitalizations in Marche were due to genital cancer (1.69 mean 
hospitalizations per patient), while in Veneto to oropharyngeal cancer with a mean of 1.96 
hospitalizations per patient.  
3.1 Hospitalization rates: 
 
Hospitalization rates on the overall population were obtained reporting the number of hospitalized 
patients on the resident population in each region. The average hospitalization rate per year over 
the period 2008-2011 was 49.4 per 100,000 individuals in Veneto, and 48.4 per 100,000 individuals 
in Marche. Overall, a decreasing trend was estimated: in Veneto there were 57.2 hospitalizations 
per 100,000 individuals in 2008, versus 39.7 in 2011 and a similar trend was reported in Marche that 
passed from a rate of 52.5 hospitalizations in 2008 to 44.9 per 100,000 individuals in 2011 (Table 3). 
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Table 3: Hospitalization rates per 100,000 individuals (Marche, Veneto) 
 
 2008 2009 2010 2011 TOT 
 
 VENETO 
 
Population 4,022,601 4,063,041 4,082,292 4,103,445 4,067,845 
Anal cancer 9.37 5.14 5.56 4.95 6.24 
Genital cancer 11.86 11.72 11.37 7.92 10.71 
Genital warts 17.15 18.07 16.44 13.45 16.27 
Oropharyngeal cancer 18.77 17.18 15.58 13.40 16.22 
Total 57.15 52.10 48.94 39.72 49.44 
 
MARCHE 
 
Population 1,305,949 1,319,368 1,310,322 1,315,600 1,312,810 
Anal cancer 6.43 7.66 6.56 6.92 6.89 
Genital cancer 24.58 24.03 22.74 22.35 23.42 
Genital warts 10.41 8.64 7.48 7.15 8.42 
Oropharyngeal cancer 11.03 7.20 11.91 8.59 9.67 
Total 52.45 47.52 48.69 45.00 48.41 
       
 
3.2 Costs: 
 
Between 2008 and 2011, each treated patient caused an average annual expense, in terms of 
hospitalizations related to cancer, of € 6,063 in Veneto and € 6,237 in Marche. Regarding genital 
warts the mean cost per patient in Veneto was € 2,107 and in Marche € 1,672. In Table 3 we report 
the cost per patient by disease and year of analysis. 
 
Table 4: Hospitalization costs per patient, year (Veneto, Marche 2008-2011) 
 
Veneto 
Year 
Anal 
cancer 
Genital 
cancer 
Oropharyngeal 
cancer 
Total 
cancer 
Genital 
warts 
2008 € 5,603.87 € 6,098.85 € 5,863.18 € 5,870.23 € 2,225.67 
2009 € 6,630.53 € 7,133.94 € 7,405.85 € 7,171.29 € 2,318.14 
2010 € 5,681.07 € 7,237.05 € 7,235.06 € 6,920.61 € 2,301.63 
2011 € 5,254.51 € 7,189.62 € 6,366.28 € 6,333.46 € 2,212.82 
Totale € 5,732.59 € 6,862.53 € 6,658.48 € 6,523.91 € 2,267.11 
 
 
Marche 
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Year Anal cancer 
Genital 
cancer 
Oropharyngeal 
cancer 
Total 
cancer 
Genital 
warts 
2008 € 5,792.20 € 6,155.52 € 9,520.35 € 6,981.79 € 1,884.31 
2009 € 6,098.84 € 6,452.51 € 7,709.77 € 6,644.12 € 1,743.43 
2010 € 6,216.27 € 6,286.85 € 9,412.27 € 7,142.75 € 1,782.72 
2011 € 6,184.64 € 6,196.78 € 5,463.17 € 6,012.57 € 1,760.92 
Totale € 6,072.11 € 6,274.08 € 8,132.65 € 6,701.67 € 1,799.29 
 
In table 5 costs are illustrated by gender for which an independent-samples t-test was conducted to 
compare the mean values. A significant difference in the scores was obtained for genital cancer in 
both Veneto (p=.009) and Marche region (p=.004). In particular, in Veneto, genital warts evidenced 
an average cost per patient equal to €4,855 per male compared to €6,870 per female; In Marche 
same costs were equal to €4,459 per male and €6,202 per female, respectively.  
 
Table 5: Hospitalization costs per patient, gender (Veneto and Marche) 
 
Diagnosis Veneto Marche 
 Male Female T-test p Male Female T-test p 
Anal cancer € 5,420.17 € 5,235.06 0.868 € 5,921.56 € 5,385.84 0.077 
Genital cancer € 4,855.26 € 6,870.71 0.009 € 4,459.80 € 6,202.54 0.004 
Oropharyngeal 
cancer € 6,227.85 € 6,061.38 0.815 € 7,532.15 € 7,613.35 0.899 
Total cancers € 5,855.39 € 6,299.95 0.306 € 6,251.75 € 6,227.56 0.929 
Genital warts € 2,129.08 € 2,096.07 0.515 € 1,647.69 € 1,692.26 0.643 
 
In conclusion, the total estimate of the annual economic impact on the regional health services was 
calculated. As a result, hospitalizations accounted, on average, for €5,78 million (SD 0.8) in Veneto 
and €2,24 million in Marche (SD 0.17), as reported in Table 6. 
Table 6: Total annual expenses due to HPV-related diseases, Veneto and Marche population (2008-10) 
  
2008 2009 2010 2011 Mean 
Veneto 
 € 6,530,353.46   € 6,142,527.60   € 5,798,918.13   € 4,657,824.46   € 5,782,405.91  
     
Marche 
 € 2,397,438.30   € 2,208,327.52   € 2,362,861.91   € 2,012,494.60   € 2,245,280.58  
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In Veneto region, the disease with the highest economic burden in terms of hospitalizations was the 
oropharyngeal cancer: €2,08 million corresponding to 36% of the total mean annual cost. In Marche 
region the highest expense was caused by genital cancers, 47% of total cost with an expense of over 
€1,06 million a year (Figure 1), versus €1,61 million in Veneto, about 28% of total average expenses. 
Furthermore, in Marche the cost of oropharyngeal cancer was estimated at €632 thousand, about 
28% of the regional burden of HPV-related diseases. Anus cancer had a limited impact in Veneto, 
€882 thousand, corresponding to 15% of the costs incurred by the regional health service. Finally, 
genital warts accounted for 8% of the expenses in Marche and 21% in Veneto. 
 
Figure 1: Expenses % by disease on mean total (Veneto, Marche 2008-2011) 
 
 
 
Overall, between 2008 and 2011 resources allocated to hospitalizations highlighted a decreasing 
trend in both regions (Figure 2). On average the study estimated a reduction of 22% between the 
first and the last year of analysis (-28.67% in Veneto and -16.06% in Marche). The decrease was 
higher in Veneto, especially between 2010 and 2011.              
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Figure 2: total mean cost (Veneto, Marche 2008-2011) 
 
 
 
3.3 Costs strictly related to the HPV virus: 
 
On average, 72% of hospitalizations were strictly related to the presence of HPV virus. As a 
consequence, the average economic impact of HPV strictly related diseases per year, was equal to 
€3,89 million in Veneto and €1,60 million in Marche (annual mean values) . The disease causing 
higher costs in terms of hospitalizations both in Veneto and Marche was genital cancer: €1,47 
million in Veneto (37.8 % of total costs) and €982,899 in Marche (61.0%). Moreover, genital warts 
in Veneto caused an expense of €1,19 million, 30.8% of total cost, while anal cancer in Marche 
costed  €290,843, 18,0% of mean total per year. In Table 7 the average costs per year are reported 
by gender and ranges as by the application of weights from literature are also illustrated.  
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Table 7: Total mean cost per gender, disease (Veneto, Marche) 
 
 
Veneto 
  Male Female Tot 
Anal cancer  € 334,926                             (€ 287,079 - € 382,772) 
€ 344,650                         
(€ 295,414 - € 393,886) 
 € 679,576                             
(€ 582,494 - € 776,659) 
Genital cancer  € 155,931                             (€ 113,185 - € 198,677) 
€ 1,315,740  € 1,471,671                           
(€ 1,428,926 - € 1,514,417) 
Genital warts € 415,170 € 783,407 € 1,198,578 
Oropharyngeal 
cancer 
 € 420,597                               
(€ 400,337 - € 440,857) 
€ 120,328                        
(€ 114,532 - € 126,125) 
 € 540,926                             
(€ 514,869 -  € 566,982) 
Marche 
  Male Female Tot 
Anal cancer 
  € 155,026                                     
(€ 132,879 - € 177,173)  
 € 135,817                        
(€ 116,414 - € 155,219)  
  € 290,843                            
(€ 249,294 - € 332,393)  
Genital cancer  € 86,631                                          (€ 62,883 - € 110,380)  
€ 896,267   € 982,899                            
(€ 959,150 - € 1,006,647)  
Genital warts € 75,793 € 95,612 € 171,406 
Oropharyngeal 
cancer 
 € 119,718                                      
(€ 113,952 - € 125,485)  
  € 44,452                         
(€ 42,311 - € 46,593)  
  € 164,171                            
(€ 156,263 - € 172,079)  
 
 
 
Considering the weightings, hospitalization rates on the resident population that were strictly 
related to HPV amounted to 34.88 per 100,000 individuals in Veneto and 37.74 in Marche. Both in 
Veneto and Marche these rates were higher for women, 43.01 and 52.31 per 100,000 individuals 
respectively, compared to 26.22 of males in Veneto and 21.98 in Marche. 
4. Discussion: 
 
This study represents a first attempt to quantify the hospitalization rates of HPV-related diseases 
[3], as well as a measure of the economic burden of these hospitalizations from the Italian National 
Health Service perspective. At the time of the analysis, the population over 18 years old amounted 
to over €5,3 million, €4 million in Veneto and €1,3 in Marche that was almost 9% of the total Italian 
population [9]. Hence, strength of the study is constituted by the size of the population analysed 
especially if we consider that data are representative of all hospitals in Veneto and Marche territory. 
By doing so, this work represents an evolution of the previous study conducted only in Veneto[3]. 
Overall, the hospitalization rates of the two regions were comparable: 49.44 hospitalizations in 
Veneto and 48.41 in Marche per 100,000 individuals. Coherently with incidence rates reported in 
literature [4, 15], the highest hospitalization rate in Veneto was due to Genital warts (16.22 per 
100,000 individuals), while in Marche genital cancers caused 23.42 hospitalized patients per 
100,000 individuals. Overall, in both regions, the hospitalization rates showed a decreasing trend 
between 2008 and 2011 that coherently with the annual report on hospital discharges 
performances by the Italian Ministry of Health [16], we expect to continue in the years to come. 
Moreover, in coherence with the new vaccination strategy adopted in Italy (both boys and girls aged 
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12) [17] and the introduction of nona-valent HPV vaccination, health gains due to primary 
prevention are expected to allow for further decreases [18].   
In both regions, the decrease was steady during the period of analysis, even if it was higher in 
Veneto: -43.88% from 2008 to 2011, compared to -16.56% in Marche. The only disease with an 
opposite trend was the anus cancer that showed a slight increase of the hospitalization rates in the 
Marche region (6.92 in 2011 compared to 6.43 in 2008 per 100,000 individuals). In Veneto, the same 
disease showed a higher decrease, passing from 9.37 in 2008 to 4.95 hospitalizations per 100,000 
individuals in the last year considered. In 2008 there was a higher number of secondary diagnoses 
compared to other years. This was due to hospitalizations related to the administration of 
chemotherapy that from 2007 started to be replaced by day-hospital chemotherapy treatments 
(Resolution of the regional Committee no. 734 of 20 March 2007: Chemotherapy and radiotherapy 
health services, Official Bulletin of the Veneto Region 2007. 37:106–109). The 2008 data were also 
due to an increase in the number of cases, as already highlighted in the previous work on Veneto 
[3]. In both regions the mean cost by disease was higher for malignant tumours (anus cancer, genital 
and oropharyngeal cancers) compared to genital warts. However, non-cancerous diseases like 
genital warts caused a considerable economic burden, especially in Veneto, where it was worth 
more than 1,19 million, 21% of the mean annual total, compared to the corresponding burden in 
the Marche region (about €171 thousand, equal to 8%). A relevant contribution of the present study 
is also due to the estimation costs strictly related to HPV virus. Although, the estimation was based 
on the literature [1, 5, 10-13] and not on administrative data, it was possible to estimate that over 
72% of the admissions related to hospitalizations were strictly linked to HPV. These hospitalizations 
caused a mean annual burden of about €3,89 million in Veneto and €1,60 million in Marche. 
Therefore, 67% of the estimated costs for the diseases being analysed can be strictly associated with 
the HPV virus in Veneto, while they account for 71% in Marche. 
 
In conclusion, the present analysis may have some limitations. First of all, the regional hospital 
discharge forms may have codification problems; therefore some information may be missing 
and/or be wrongly reported. In this case, our analysis may have missed this information (due to the 
inclusion criteria), with the risk of underestimating the economic and epidemiological burden of the 
considered HPV-related diseases. Additionally, not all diseases led to hospitalization and this may 
be a further cause of underestimation. Therefore, the hospitalizations are underestimates of the 
generic prevalence referred to the population thus it may be assumed that the missing information 
does not significantly invalidate the results. Furthermore, due to a lack of available data, direct costs 
attributable to GPs additional treatments were not included as well as cost related to Recurrent 
Respiratory Papillomatosis (RRP) disease that, although rare, could be relevant to the overall 
estimate of the hospitalization costs of HPV induced malignancies. Lastly, it may be deemed that 
the reference time span (2008-2011) is too short, especially if compared to the previous study based 
only on Veneto [3], or the national burden estimates based on the literature. Being limited to two 
regions, the analysis may not be very significant. However, these regions accounted for almost 9% 
of the total number of patients in Italy and, for management and epidemiological characteristics, 
Marche and Veneto are two of the best-performing regions in terms of health service management. 
They may represent good examples to study the economic impact of the HPV-related diseases in 
Italy. 
5. Conclusions: 
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This work represents a useful tool to quantify the economic burden of the HPV-related diseases in 
terms of hospitalizations. The expenses observed in the two regions represent a significant cost and 
management driver also in view of the decisions in terms of HPV prevention policies nationally. 
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